Cordlife Group Ltd represents a commitment to providing advanced cord blood and tissue banking services. Their corporate philosophy revolves around prioritizing the healthcare needs of families. Cordlife aims to offer secure storage for umbilical cord blood, which contains valuable stem cells that have potential therapeutic applications. They believe in empowering individuals and the medical community with access to these life-saving resources, helping to pave the way for advancements in regenerative medicine. Cordlife Group Ltd recognizes the importance of investing in technology and research to continually improve their services and contribute to the field of stem cell science.

Cordlife Group Ltd is primarily present in several countries and regions. The company has a strong presence in Singapore, where it is headquartered. It is also actively operating in Hong Kong, India, Indonesia, Malaysia, and the Philippines. Cordlife Group Ltd has established cord blood banks and stem cell facilities in these countries, offering various services and products related to cord blood banking and umbilical cord stem cell preservation. With its extensive network and expertise, Cordlife Group Ltd continues to expand and provide reliable services to families seeking to store their newborn's cord blood for future medical use.

Cordlife Group Ltd has achieved several significant milestones in its history. One of the notable achievements was the successful IPO listing on the Singapore Exchange Securities Trading Limited in 2011. This milestone not only demonstrated the company's strong market position but also opened up new opportunities for growth and expansion. Furthermore, Cordlife Group Ltd has consistently expanded its presence in the international market, establishing a strong foothold in countries like Hong Kong, India, and the Philippines. Additionally, the company has received several prestigious awards and recognition for its commitment to quality and excellence in stem cell banking services. These achievements have solidified Cordlife Group Ltd's position as a leading player in the industry.

Cordlife Group Ltd is a leading consumer healthcare group, dedicated to providing stem cell banking and cord blood services. Founded in 2001, Cordlife has a rich history of delivering high-quality stem cell banking solutions to families in Asia-Pacific. With a strong focus on innovation and research, Cordlife has established a reputation for its state-of-the-art laboratory facilities and commitment to exceptional service. As a pioneer in the field, Cordlife has successfully stored and preserved thousands of cord blood units, offering opportunities for future medical treatments and therapies. With a strong track record and a dedicated team of professionals, Cordlife Group Ltd continues to pave the way in the stem cell banking industry.

The main competitors of Cordlife Group Ltd in the market are StemLife, Cryoviva, and Cryo-Save.

Cordlife Group Ltd is primarily active in the healthcare industry.

Cordlife Group Ltd operates with a business model focused on providing cord blood banking and cord tissue banking services. As a leading consumer healthcare company, Cordlife Group offers expectant parents the opportunity to store their baby's umbilical cord blood and tissue, which contain potentially life-saving stem cells. These stem cells can be used in the future for various medical treatments, including cancer, blood disorders, and immune system disorders. Cordlife Group ensures that the collected stem cells are processed, tested, and stored under strict quality standards, ensuring their viability and safety for potential future use.

Cordlife Group için şu anki KGV hesaplanamıyor.

Cordlife Group için mevcut KUV şu anda hesaplanamıyor.

Cordlife Group için AlleAktien Kalite Skoru 2/10'dur.

Cordlife Group için şu an ciro hesaplanamıyor.

Cordlife Group için şu anda kar hesaplanamıyor.

Cordlife Group Ltd is a biotechnology company specializing in stem cell storage. The company offers various products and services tailored to the needs of families and medical professionals. Cordlife operates stem cell storage banks in various countries, including Australia, Hong Kong, India, Indonesia, Malaysia, Philippines, Singapore, and Thailand. The facilities are certified to the highest international quality standards and provide a safe and reliable solution for stem cell storage. The company offers various stem cell products, including umbilical cord blood, umbilical cord tissue, and placental tissue. These products can be used for various diseases and conditions, such as leukemia, sickle cell anemia, thalassemia, autism, cerebral palsy, and diabetes. Cordlife also offers services for the collection of umbilical cord blood and umbilical cord tissue. The company works with selected medical facilities to ensure safe and effective collection. Umbilical cord blood collection is a simple and non-invasive method that can be done during childbirth. Cordlife also has a research and development department focused on the development of new technologies and products. The company strives to constantly improve its services and provide innovative solutions to enhance the health and well-being of people worldwide. The business model of Cordlife Group Ltd is based on stem cell storage and providing products and services tailored to the needs of families and medical professionals. The company utilizes state-of-the-art technologies and facilities to ensure safe and effective storage and collection of stem cells. The company has a strong focus on research and development of new technologies and products to ensure it stays at the forefront of science. This allows the company to improve its services and offer innovative solutions to enhance the health and well-being of people worldwide. Cordlife Group Ltd has a strong presence in Asia and is constantly expanding into new regions and countries. The company works closely with medical facilities and professionals to continuously improve and optimize its services. In conclusion, Cordlife Group Ltd is a biotechnology company specializing in stem cell storage and provision of stem cell products and services. The company has a strong focus on research and development of new technologies and products to ensure it stays at the forefront of science. With its strong emphasis on quality and customer service, Cordlife Group Ltd is expected to remain a leading player in the biotechnology industry.

Cordlife Group, yılda kez dağıtılmak üzere 0,01 SGD tutarında temettü ödemektedir.

Cordlife Group için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Cordlife Group şirketinin ISIN kodu SG2E64980112’dir.

Cordlife Group 'nin WKN'si A1JWVR 'dir.

Cordlife Group için Ticker P8A.SI’dir.

Son 12 ay içerisinde Cordlife Group, 0,01 SGD tutarında bir temettü ödedi. Bu, yaklaşık olarak 6,00 % oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Cordlife Group, tahmini olarak 0,01 SGD tutarında bir temettü ödemesi yapacak.

Cordlife Group şirketinin mevcut temettü verimi 6,00 %.

Cordlife Group dönemsel olarak temettü ödemesi yapar. Bu ödemeler Mayıs, Temmuz, Haziran, Haziran aylarında gerçekleştirilir.

Cordlife Group, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0,01 SGD tutarında temettü ödenmesi beklenmektedir. Bu, 6,00 % oranında bir temettü verimidir.

Cordlife Group, 'Sağlık' sektörüne atanmıştır.

Son Cordlife Group tarihinde 0,009 SGD tutarındaki en son temettüyü alabilmek için, hisseyi 06.05.2022 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 27.05.2022 olarak gerçekleşti.

2023 yılında Cordlife Group tarafından 0,009 SGD olarak temettüler dağıtıldı.

Cordlife Group hisselerinin temettüleri SGD olarak dağıtılır.